Head-To-Head Analysis: TriSalus Life Sciences (TLSI) versus Its Peers

TriSalus Life Sciences (NASDAQ:TLSI) is one of 236 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its rivals? We will compare TriSalus Life Sciences to related companies based on the strength of its institutional ownership, valuation, analyst recommendations, profitability, earnings, risk and dividends.

Profitability

This table compares TriSalus Life Sciences and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-219.71%	N/A	-192.99%
TriSalus Life Sciences Competitors	-548.27%	-135.22%	-26.53%

Earnings & Valuation

This table compares TriSalus Life Sciences and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
TriSalus Life Sciences	$24.74 million	-$59.04 million	-1.79
TriSalus Life Sciences Competitors	$1.03 billion	$9.23 million	-21.62

TriSalus Life Sciences’ rivals have higher revenue and earnings than TriSalus Life Sciences. TriSalus Life Sciences is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of recent ratings and price targets for TriSalus Life Sciences and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	0	0	6	1	3.14
TriSalus Life Sciences Competitors	1889	4865	9107	266	2.48

TriSalus Life Sciences presently has a consensus price target of $12.25, indicating a potential upside of 173.44%. As a group, “Surgical & medical instruments” companies have a potential upside of 13.73%. Given TriSalus Life Sciences’ stronger consensus rating and higher possible upside, equities research analysts plainly believe TriSalus Life Sciences is more favorable than its rivals.

Insider and Institutional Ownership

2.6% of TriSalus Life Sciences shares are owned by institutional investors. Comparatively, 48.0% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 32.8% of TriSalus Life Sciences shares are owned by insiders. Comparatively, 15.1% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

TriSalus Life Sciences has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500. Comparatively, TriSalus Life Sciences’ rivals have a beta of 0.46, indicating that their average stock price is 54% less volatile than the S&P 500.

Summary

TriSalus Life Sciences beats its rivals on 9 of the 13 factors compared.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.